STOK analyst estimates
Stoke Therapeutics (STOK) analyst ratings, the average price target and its range, and every firm's latest call.
STOK analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | Goldman Sachs | Stoke Therapeutics (STOK) PT Lowered to $43 at Goldman Sachs | $43.00 |
| Aug 4, 2026 | Canaccord Genuity | Stoke Therapeutics price target lowered to $58 from $60 at Canaccord | $58.00 |
| Jul 13, 2026 | Goldman Sachs | Stoke Therapeutics initiated with a Buy at Goldman Sachs | $44.00 |
| Feb 23, 2026 | Wolfe Research | Stoke Therapeutics initiated with an Outperform at Wolfe Research | $40.00 |
| Feb 5, 2026 | Guggenheim | Stoke Therapeutics initiated with a Buy at Guggenheim | $60.00 |
| Jan 12, 2026 | Wedbush | Stoke Therapeutics price target raised to $36 from $32 at Wedbush | $36.00 |
| Jan 5, 2026 | Loop Capital Markets | Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy | $35.00 |
| Jan 5, 2026 | Canaccord Genuity | Stoke Therapeutics price target raised to $36 from $28 at Canaccord | $36.00 |
| Dec 16, 2025 | H.C. Wainwright | Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright | $50.00 |
| Dec 15, 2025 | UBS | Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright | $50.00 |
| Nov 5, 2025 | Canaccord Genuity | Stoke Therapeutics price target raised to $28 from $24 at Canaccord | $28.00 |
| Oct 10, 2025 | Needham | Stoke Therapeutics price target raised to $35 from $22 at Needham | $35.00 |
| Aug 18, 2025 | BTIG | Stoke Therapeutics price target lowered to $28 from $29 at BTIG | $28.00 |
| Oct 11, 2024 | Leerink Partners | Stoke Therapeutics assumed with an Outperform at Leerink | $18.00 |
| Sep 11, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK) | $35.00 |
- 10 firms rate STOK: 10 buy, 0 hold, 0 sell.
- The average price target is $50.50 from 2 analysts, from $43.00 to $58.00.
Updated 2026-11-07 11:50 UTC